Show simple item record

dc.contributor.authorWalvick, Ronn P.
dc.contributor.authorBratane, Bernt T.
dc.contributor.authorHenninger, Nils
dc.contributor.authorSicard, Kenneth M.
dc.contributor.authorBouley, James P.
dc.contributor.authorYu, Zhanyang
dc.contributor.authorLo, Eng H.
dc.contributor.authorWang, Xiaoying
dc.contributor.authorFisher, Marc
dc.date2022-08-11T08:09:28.000
dc.date.accessioned2022-08-23T16:31:47Z
dc.date.available2022-08-23T16:31:47Z
dc.date.issued2011-04-01
dc.date.submitted2012-05-16
dc.identifier.citation<p>Stroke. 2011 Apr;42(4):1110-5. Epub 2011 Mar 3. <a href="http://dx.doi.org/10.1161/STROKEAHA.110.602102" target="_blank">Link to article on publisher's site</a></p>
dc.identifier.issn0039-2499 (Linking)
dc.identifier.doi10.1161/STROKEAHA.110.602102
dc.identifier.pmid21372305
dc.identifier.urihttp://hdl.handle.net/20.500.14038/37733
dc.description.abstractBACKGROUND AND PURPOSE: The purpose of this study was to develop a novel MRI method for imaging clot lysis in a rat embolic stroke model and to compare tissue plasminogen activator (tPA)-based clot lysis with and without recombinant Annexin-2 (rA2). METHODS: In experiment 1 we used in vitro optimization of clot visualization using multiple MRI contrast agents in concentrations ranging from 5 to 50 muL in 250 muL blood. In experiment 2, we used in vivo characterization of the time course of clot lysis using the clot developed in the previous experiment. Diffusion, perfusion, angiography, and T1-weighted MRI for clot imaging were conducted before and during treatment with vehicle (n=6), tPA (n=8), or rA2 plus tPA (n=8) at multiple time points. Brains were removed for ex vivo clot localization. RESULTS: Clots created with 25 muL Magnevist were the most stable and provided the highest contrast-to-noise ratio. In the vehicle group, clot length as assessed by T1-weighted imaging correlated with histology (r=0.93). Clot length and cerebral blood flow-derived ischemic lesion volume were significantly smaller than vehicle at 15 minutes after treatment initiation in the rA2 plus tPA group, whereas in the tPA group no significant reduction from vehicle was observed until 30 minutes after treatment initiation. The rA2 plus tPA group had a significantly shorter clot length than the tPA group at 60 and 90 minutes after treatment initiation and significantly smaller cerebral blood flow deficit than the tPA group at 90 minutes after treatment initiation. CONCLUSIONS: We introduce a novel MRI-based clot imaging method for in vivo monitoring of clot lysis. Lytic efficacy of tPA was enhanced by rA2.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=21372305&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094728/pdf/nihms278590.pdf
dc.subjectAnimals
dc.subjectAnnexin A2
dc.subjectDisease Models, Animal
dc.subjectDrug Therapy, Combination
dc.subjectFibrin
dc.subjectFibrinogen
dc.subjectFibrinolysis
dc.subjectFibrinolytic Agents
dc.subjectIntracranial Embolism
dc.subjectIntracranial Thrombosis
dc.subjectMagnetic Resonance Imaging
dc.subjectMale
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectRecombinant Proteins
dc.subjectThrombolytic Therapy
dc.subjectNeurology
dc.subjectNeuroscience and Neurobiology
dc.titleVisualization of clot lysis in a rat embolic stroke model: application to comparative lytic efficacy
dc.typeJournal Article
dc.source.journaltitleStroke; a journal of cerebral circulation
dc.source.volume42
dc.source.issue4
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/neuro_pp/408
dc.identifier.contextkey2852790
html.description.abstract<p>BACKGROUND AND PURPOSE: The purpose of this study was to develop a novel MRI method for imaging clot lysis in a rat embolic stroke model and to compare tissue plasminogen activator (tPA)-based clot lysis with and without recombinant Annexin-2 (rA2).</p> <p>METHODS: In experiment 1 we used in vitro optimization of clot visualization using multiple MRI contrast agents in concentrations ranging from 5 to 50 muL in 250 muL blood. In experiment 2, we used in vivo characterization of the time course of clot lysis using the clot developed in the previous experiment. Diffusion, perfusion, angiography, and T1-weighted MRI for clot imaging were conducted before and during treatment with vehicle (n=6), tPA (n=8), or rA2 plus tPA (n=8) at multiple time points. Brains were removed for ex vivo clot localization.</p> <p>RESULTS: Clots created with 25 muL Magnevist were the most stable and provided the highest contrast-to-noise ratio. In the vehicle group, clot length as assessed by T1-weighted imaging correlated with histology (r=0.93). Clot length and cerebral blood flow-derived ischemic lesion volume were significantly smaller than vehicle at 15 minutes after treatment initiation in the rA2 plus tPA group, whereas in the tPA group no significant reduction from vehicle was observed until 30 minutes after treatment initiation. The rA2 plus tPA group had a significantly shorter clot length than the tPA group at 60 and 90 minutes after treatment initiation and significantly smaller cerebral blood flow deficit than the tPA group at 90 minutes after treatment initiation.</p> <p>CONCLUSIONS: We introduce a novel MRI-based clot imaging method for in vivo monitoring of clot lysis. Lytic efficacy of tPA was enhanced by rA2.</p>
dc.identifier.submissionpathneuro_pp/408
dc.contributor.departmentDepartment of Radiology
dc.contributor.departmentDepartment of Neurology
dc.source.pages1110-5


This item appears in the following Collection(s)

Show simple item record